Accredited Activities

Incorporating Clinical Trials Data into the Management of DR, AMD, RVO, mCNV, and PCV

This engaging activity is designed for ophthalmology residents and retina fellows to improve familiarity with new and emerging clinical trial data for retinal vascular diseases. Through better understanding of clinical trial structures, efficacy and safety outcomes for studied anti-VEGF agents, this data can be utilized to enhance the creation of evidence-based treatment plans for patients with DR, AMD, RVO, mCNV, and PCV.

ONLINE ACTIVITIES

Apr
29
Fri
Incorporating Clinical Trials Data into the Management of DR, AMD, RVO, mCNV, and PCV
Apr 29 2022 @ 8:00 am – Apr 29 2023 @ 9:00 am

Incorporating Clinical Trials Data into the Management of DR, AMD, RVO, mCNV, and PCV

VIEW ACTIVITY

FACULTY

Rishi P. Singh, MD
Staff Physician, Cleveland Clinic Florida
Professor of Ophthalmology
Cleveland Clinic Lerner College of Medicine
Stuart, FL

PROGRAM OVERVIEW

This enduring activity targets healthcare gaps related to the early intervention of retinal vascular diseases and familiarity with new and emerging clinical trial data, impacting outcomes through assessment and synthesis of clinical trial structures, and outcomes of studied anti-VEGF agents for incorporation into treatment strategy development.

  • By addressing these gaps, you can assess whether your approach to DR, AMD, RVO, mCNV, and PCV management best applies clinical trial data to create individualized treatment regimens – or could be modified to help close these gaps.
  • Expert discussion will guide you in comparing different modalities of treatment, including efficacy, durability, and challenges related to timely treatment.
  • You will also be engaged with immersive animations in a whiteboard platform to memorably highlight key points related to clinical trials in mCNV, and PCV.
TARGET AUDIENCE

This activity is designed to meet the educational needs of clinicians in ophthalmology or retina fellowships who manage patients with Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), Retinal Vein Occlusion (RVO), Myopic Choroidal Neovascularization (mCNV), and Polypoidal Choroidal Vasculopathy (PCV).

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Utilize an understanding of the pathogenesis of DR, AMD, RVO, mCNV, and PCV to educate patients on the importance of proper eye care and early intervention in preventing progressive visual changes
  • Evaluate clinical trial data on the efficacy and safety of VEGF inhibitors in the management of DR, AMD, RVO, mCNV, and PCV
  • Incorporate clinical trial data into evidence-based treatment plans for the management of patients with DR, AMD, RVO, mCNV, and PCV
ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with diabetic retinopathy.
CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Rishi P. Singh, MD discloses the following:

  • Sponsored research: NGM Biopharmaceuticals
  • Consulting: Bausch + Lomb, AsclepiX Therapeutics, Gyroscope, Apellis Pharmaceuticals, Genentech, Novartis, Regeneron Pharmaceuticals, and ZEISS
CME Content Review

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
  • Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
  • Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
  • Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
  • Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
  • Daniel Dasilva, Outcomes and Accreditation Coordinator of Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

RELEASE DATE: April 29, 2022

EXPIRATION DATE: April 29, 2023

PROGRAM OVERVIEW

This enduring activity targets healthcare gaps related to the early intervention of retinal vascular diseases and familiarity with new and emerging clinical trial data, impacting outcomes through assessment and synthesis of clinical trial structures, and outcomes of studied anti-VEGF agents for incorporation into treatment strategy development.

  • By addressing these gaps, you can assess whether your approach to DR, AMD, RVO, mCNV, and PCV management best applies clinical trial data to create individualized treatment regimens – or could be modified to help close these gaps.
  • Expert discussion will guide you in comparing different modalities of treatment, including efficacy, durability, and challenges related to timely treatment.
  • You will also be engaged with immersive animations in a whiteboard platform to memorably highlight key points related to clinical trials in mCNV, and PCV.
TARGET AUDIENCE

This activity is designed to meet the educational needs of clinicians in ophthalmology or retina fellowships who manage patients with Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), Retinal Vein Occlusion (RVO), Myopic Choroidal Neovascularization (mCNV), and Polypoidal Choroidal Vasculopathy (PCV).

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Utilize an understanding of the pathogenesis of DR, AMD, RVO, mCNV, and PCV to educate patients on the importance of proper eye care and early intervention in preventing progressive visual changes
  • Evaluate clinical trial data on the efficacy and safety of VEGF inhibitors in the management of DR, AMD, RVO, mCNV, and PCV
  • Incorporate clinical trial data into evidence-based treatment plans for the management of patients with DR, AMD, RVO, mCNV, and PCV
ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with diabetic retinopathy.
CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Rishi P. Singh, MD discloses the following:

  • Sponsored research: NGM Biopharmaceuticals
  • Consulting: Bausch + Lomb, AsclepiX Therapeutics, Gyroscope, Apellis Pharmaceuticals, Genentech, Novartis, Regeneron Pharmaceuticals, and ZEISS
CME Content Review

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
  • Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
  • Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
  • Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
  • Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
  • Daniel Dasilva, Outcomes and Accreditation Coordinator of Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

RELEASE DATE: April 29, 2022

EXPIRATION DATE: April 29, 2023

Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

VIEW ACTIVITY

CLICK ON STATES TO SEE LIVE ACTIVITIES

ONLINE ACTIVITIES

Apr
29
Fri
Incorporating Clinical Trials Data into the Management of DR, AMD, RVO, mCNV, and PCV
Apr 29 2022 @ 8:00 am – Apr 29 2023 @ 9:00 am

Incorporating Clinical Trials Data into the Management of DR, AMD, RVO, mCNV, and PCV

VIEW ACTIVITY

FACULTY

Rishi P. Singh, MD
Staff Physician, Cleveland Clinic Florida
Professor of Ophthalmology
Cleveland Clinic Lerner College of Medicine
Stuart, FL

PROGRAM OVERVIEW

This enduring activity targets healthcare gaps related to the early intervention of retinal vascular diseases and familiarity with new and emerging clinical trial data, impacting outcomes through assessment and synthesis of clinical trial structures, and outcomes of studied anti-VEGF agents for incorporation into treatment strategy development.

  • By addressing these gaps, you can assess whether your approach to DR, AMD, RVO, mCNV, and PCV management best applies clinical trial data to create individualized treatment regimens – or could be modified to help close these gaps.
  • Expert discussion will guide you in comparing different modalities of treatment, including efficacy, durability, and challenges related to timely treatment.
  • You will also be engaged with immersive animations in a whiteboard platform to memorably highlight key points related to clinical trials in mCNV, and PCV.
TARGET AUDIENCE

This activity is designed to meet the educational needs of clinicians in ophthalmology or retina fellowships who manage patients with Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), Retinal Vein Occlusion (RVO), Myopic Choroidal Neovascularization (mCNV), and Polypoidal Choroidal Vasculopathy (PCV).

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Utilize an understanding of the pathogenesis of DR, AMD, RVO, mCNV, and PCV to educate patients on the importance of proper eye care and early intervention in preventing progressive visual changes
  • Evaluate clinical trial data on the efficacy and safety of VEGF inhibitors in the management of DR, AMD, RVO, mCNV, and PCV
  • Incorporate clinical trial data into evidence-based treatment plans for the management of patients with DR, AMD, RVO, mCNV, and PCV
ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with diabetic retinopathy.
CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Rishi P. Singh, MD discloses the following:

  • Sponsored research: NGM Biopharmaceuticals
  • Consulting: Bausch + Lomb, AsclepiX Therapeutics, Gyroscope, Apellis Pharmaceuticals, Genentech, Novartis, Regeneron Pharmaceuticals, and ZEISS
CME Content Review

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
  • Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
  • Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
  • Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
  • Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
  • Daniel Dasilva, Outcomes and Accreditation Coordinator of Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

RELEASE DATE: April 29, 2022

EXPIRATION DATE: April 29, 2023

PROGRAM OVERVIEW

This enduring activity targets healthcare gaps related to the early intervention of retinal vascular diseases and familiarity with new and emerging clinical trial data, impacting outcomes through assessment and synthesis of clinical trial structures, and outcomes of studied anti-VEGF agents for incorporation into treatment strategy development.

  • By addressing these gaps, you can assess whether your approach to DR, AMD, RVO, mCNV, and PCV management best applies clinical trial data to create individualized treatment regimens – or could be modified to help close these gaps.
  • Expert discussion will guide you in comparing different modalities of treatment, including efficacy, durability, and challenges related to timely treatment.
  • You will also be engaged with immersive animations in a whiteboard platform to memorably highlight key points related to clinical trials in mCNV, and PCV.
TARGET AUDIENCE

This activity is designed to meet the educational needs of clinicians in ophthalmology or retina fellowships who manage patients with Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), Retinal Vein Occlusion (RVO), Myopic Choroidal Neovascularization (mCNV), and Polypoidal Choroidal Vasculopathy (PCV).

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Utilize an understanding of the pathogenesis of DR, AMD, RVO, mCNV, and PCV to educate patients on the importance of proper eye care and early intervention in preventing progressive visual changes
  • Evaluate clinical trial data on the efficacy and safety of VEGF inhibitors in the management of DR, AMD, RVO, mCNV, and PCV
  • Incorporate clinical trial data into evidence-based treatment plans for the management of patients with DR, AMD, RVO, mCNV, and PCV
ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with diabetic retinopathy.
CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Rishi P. Singh, MD discloses the following:

  • Sponsored research: NGM Biopharmaceuticals
  • Consulting: Bausch + Lomb, AsclepiX Therapeutics, Gyroscope, Apellis Pharmaceuticals, Genentech, Novartis, Regeneron Pharmaceuticals, and ZEISS
CME Content Review

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
  • Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
  • Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
  • Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
  • Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
  • Daniel Dasilva, Outcomes and Accreditation Coordinator of Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

RELEASE DATE: April 29, 2022

EXPIRATION DATE: April 29, 2023

Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

VIEW ACTIVITY

BOOTH TOUR

Apr
29
Fri
Incorporating Clinical Trials Data into the Management of DR, AMD, RVO, mCNV, and PCV
Apr 29 2022 @ 8:00 am – Apr 29 2023 @ 9:00 am

Incorporating Clinical Trials Data into the Management of DR, AMD, RVO, mCNV, and PCV

VIEW ACTIVITY

FACULTY

Rishi P. Singh, MD
Staff Physician, Cleveland Clinic Florida
Professor of Ophthalmology
Cleveland Clinic Lerner College of Medicine
Stuart, FL

PROGRAM OVERVIEW

This enduring activity targets healthcare gaps related to the early intervention of retinal vascular diseases and familiarity with new and emerging clinical trial data, impacting outcomes through assessment and synthesis of clinical trial structures, and outcomes of studied anti-VEGF agents for incorporation into treatment strategy development.

  • By addressing these gaps, you can assess whether your approach to DR, AMD, RVO, mCNV, and PCV management best applies clinical trial data to create individualized treatment regimens – or could be modified to help close these gaps.
  • Expert discussion will guide you in comparing different modalities of treatment, including efficacy, durability, and challenges related to timely treatment.
  • You will also be engaged with immersive animations in a whiteboard platform to memorably highlight key points related to clinical trials in mCNV, and PCV.
TARGET AUDIENCE

This activity is designed to meet the educational needs of clinicians in ophthalmology or retina fellowships who manage patients with Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), Retinal Vein Occlusion (RVO), Myopic Choroidal Neovascularization (mCNV), and Polypoidal Choroidal Vasculopathy (PCV).

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Utilize an understanding of the pathogenesis of DR, AMD, RVO, mCNV, and PCV to educate patients on the importance of proper eye care and early intervention in preventing progressive visual changes
  • Evaluate clinical trial data on the efficacy and safety of VEGF inhibitors in the management of DR, AMD, RVO, mCNV, and PCV
  • Incorporate clinical trial data into evidence-based treatment plans for the management of patients with DR, AMD, RVO, mCNV, and PCV
ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with diabetic retinopathy.
CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Rishi P. Singh, MD discloses the following:

  • Sponsored research: NGM Biopharmaceuticals
  • Consulting: Bausch + Lomb, AsclepiX Therapeutics, Gyroscope, Apellis Pharmaceuticals, Genentech, Novartis, Regeneron Pharmaceuticals, and ZEISS
CME Content Review

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
  • Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
  • Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
  • Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
  • Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
  • Daniel Dasilva, Outcomes and Accreditation Coordinator of Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

RELEASE DATE: April 29, 2022

EXPIRATION DATE: April 29, 2023

PROGRAM OVERVIEW

This enduring activity targets healthcare gaps related to the early intervention of retinal vascular diseases and familiarity with new and emerging clinical trial data, impacting outcomes through assessment and synthesis of clinical trial structures, and outcomes of studied anti-VEGF agents for incorporation into treatment strategy development.

  • By addressing these gaps, you can assess whether your approach to DR, AMD, RVO, mCNV, and PCV management best applies clinical trial data to create individualized treatment regimens – or could be modified to help close these gaps.
  • Expert discussion will guide you in comparing different modalities of treatment, including efficacy, durability, and challenges related to timely treatment.
  • You will also be engaged with immersive animations in a whiteboard platform to memorably highlight key points related to clinical trials in mCNV, and PCV.
TARGET AUDIENCE

This activity is designed to meet the educational needs of clinicians in ophthalmology or retina fellowships who manage patients with Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), Retinal Vein Occlusion (RVO), Myopic Choroidal Neovascularization (mCNV), and Polypoidal Choroidal Vasculopathy (PCV).

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Utilize an understanding of the pathogenesis of DR, AMD, RVO, mCNV, and PCV to educate patients on the importance of proper eye care and early intervention in preventing progressive visual changes
  • Evaluate clinical trial data on the efficacy and safety of VEGF inhibitors in the management of DR, AMD, RVO, mCNV, and PCV
  • Incorporate clinical trial data into evidence-based treatment plans for the management of patients with DR, AMD, RVO, mCNV, and PCV
ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with diabetic retinopathy.
CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Rishi P. Singh, MD discloses the following:

  • Sponsored research: NGM Biopharmaceuticals
  • Consulting: Bausch + Lomb, AsclepiX Therapeutics, Gyroscope, Apellis Pharmaceuticals, Genentech, Novartis, Regeneron Pharmaceuticals, and ZEISS
CME Content Review

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
  • Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
  • Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
  • Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
  • Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
  • Daniel Dasilva, Outcomes and Accreditation Coordinator of Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

RELEASE DATE: April 29, 2022

EXPIRATION DATE: April 29, 2023

Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

VIEW ACTIVITY

GRAND ROUNDS

Apr
29
Fri
Incorporating Clinical Trials Data into the Management of DR, AMD, RVO, mCNV, and PCV
Apr 29 2022 @ 8:00 am – Apr 29 2023 @ 9:00 am

Incorporating Clinical Trials Data into the Management of DR, AMD, RVO, mCNV, and PCV

VIEW ACTIVITY

FACULTY

Rishi P. Singh, MD
Staff Physician, Cleveland Clinic Florida
Professor of Ophthalmology
Cleveland Clinic Lerner College of Medicine
Stuart, FL

PROGRAM OVERVIEW

This enduring activity targets healthcare gaps related to the early intervention of retinal vascular diseases and familiarity with new and emerging clinical trial data, impacting outcomes through assessment and synthesis of clinical trial structures, and outcomes of studied anti-VEGF agents for incorporation into treatment strategy development.

  • By addressing these gaps, you can assess whether your approach to DR, AMD, RVO, mCNV, and PCV management best applies clinical trial data to create individualized treatment regimens – or could be modified to help close these gaps.
  • Expert discussion will guide you in comparing different modalities of treatment, including efficacy, durability, and challenges related to timely treatment.
  • You will also be engaged with immersive animations in a whiteboard platform to memorably highlight key points related to clinical trials in mCNV, and PCV.
TARGET AUDIENCE

This activity is designed to meet the educational needs of clinicians in ophthalmology or retina fellowships who manage patients with Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), Retinal Vein Occlusion (RVO), Myopic Choroidal Neovascularization (mCNV), and Polypoidal Choroidal Vasculopathy (PCV).

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Utilize an understanding of the pathogenesis of DR, AMD, RVO, mCNV, and PCV to educate patients on the importance of proper eye care and early intervention in preventing progressive visual changes
  • Evaluate clinical trial data on the efficacy and safety of VEGF inhibitors in the management of DR, AMD, RVO, mCNV, and PCV
  • Incorporate clinical trial data into evidence-based treatment plans for the management of patients with DR, AMD, RVO, mCNV, and PCV
ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with diabetic retinopathy.
CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Rishi P. Singh, MD discloses the following:

  • Sponsored research: NGM Biopharmaceuticals
  • Consulting: Bausch + Lomb, AsclepiX Therapeutics, Gyroscope, Apellis Pharmaceuticals, Genentech, Novartis, Regeneron Pharmaceuticals, and ZEISS
CME Content Review

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
  • Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
  • Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
  • Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
  • Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
  • Daniel Dasilva, Outcomes and Accreditation Coordinator of Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

RELEASE DATE: April 29, 2022

EXPIRATION DATE: April 29, 2023

PROGRAM OVERVIEW

This enduring activity targets healthcare gaps related to the early intervention of retinal vascular diseases and familiarity with new and emerging clinical trial data, impacting outcomes through assessment and synthesis of clinical trial structures, and outcomes of studied anti-VEGF agents for incorporation into treatment strategy development.

  • By addressing these gaps, you can assess whether your approach to DR, AMD, RVO, mCNV, and PCV management best applies clinical trial data to create individualized treatment regimens – or could be modified to help close these gaps.
  • Expert discussion will guide you in comparing different modalities of treatment, including efficacy, durability, and challenges related to timely treatment.
  • You will also be engaged with immersive animations in a whiteboard platform to memorably highlight key points related to clinical trials in mCNV, and PCV.
TARGET AUDIENCE

This activity is designed to meet the educational needs of clinicians in ophthalmology or retina fellowships who manage patients with Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), Retinal Vein Occlusion (RVO), Myopic Choroidal Neovascularization (mCNV), and Polypoidal Choroidal Vasculopathy (PCV).

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Utilize an understanding of the pathogenesis of DR, AMD, RVO, mCNV, and PCV to educate patients on the importance of proper eye care and early intervention in preventing progressive visual changes
  • Evaluate clinical trial data on the efficacy and safety of VEGF inhibitors in the management of DR, AMD, RVO, mCNV, and PCV
  • Incorporate clinical trial data into evidence-based treatment plans for the management of patients with DR, AMD, RVO, mCNV, and PCV
ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with diabetic retinopathy.
CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Rishi P. Singh, MD discloses the following:

  • Sponsored research: NGM Biopharmaceuticals
  • Consulting: Bausch + Lomb, AsclepiX Therapeutics, Gyroscope, Apellis Pharmaceuticals, Genentech, Novartis, Regeneron Pharmaceuticals, and ZEISS
CME Content Review

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
  • Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
  • Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
  • Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
  • Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
  • Daniel Dasilva, Outcomes and Accreditation Coordinator of Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

RELEASE DATE: April 29, 2022

EXPIRATION DATE: April 29, 2023

Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

VIEW ACTIVITY

Apr
29
Fri
Incorporating Clinical Trials Data into the Management of DR, AMD, RVO, mCNV, and PCV
Apr 29 2022 @ 8:00 am – Apr 29 2023 @ 9:00 am

Incorporating Clinical Trials Data into the Management of DR, AMD, RVO, mCNV, and PCV

VIEW ACTIVITY

FACULTY

Rishi P. Singh, MD
Staff Physician, Cleveland Clinic Florida
Professor of Ophthalmology
Cleveland Clinic Lerner College of Medicine
Stuart, FL

PROGRAM OVERVIEW

This enduring activity targets healthcare gaps related to the early intervention of retinal vascular diseases and familiarity with new and emerging clinical trial data, impacting outcomes through assessment and synthesis of clinical trial structures, and outcomes of studied anti-VEGF agents for incorporation into treatment strategy development.

  • By addressing these gaps, you can assess whether your approach to DR, AMD, RVO, mCNV, and PCV management best applies clinical trial data to create individualized treatment regimens – or could be modified to help close these gaps.
  • Expert discussion will guide you in comparing different modalities of treatment, including efficacy, durability, and challenges related to timely treatment.
  • You will also be engaged with immersive animations in a whiteboard platform to memorably highlight key points related to clinical trials in mCNV, and PCV.
TARGET AUDIENCE

This activity is designed to meet the educational needs of clinicians in ophthalmology or retina fellowships who manage patients with Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), Retinal Vein Occlusion (RVO), Myopic Choroidal Neovascularization (mCNV), and Polypoidal Choroidal Vasculopathy (PCV).

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Utilize an understanding of the pathogenesis of DR, AMD, RVO, mCNV, and PCV to educate patients on the importance of proper eye care and early intervention in preventing progressive visual changes
  • Evaluate clinical trial data on the efficacy and safety of VEGF inhibitors in the management of DR, AMD, RVO, mCNV, and PCV
  • Incorporate clinical trial data into evidence-based treatment plans for the management of patients with DR, AMD, RVO, mCNV, and PCV
ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with diabetic retinopathy.
CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Rishi P. Singh, MD discloses the following:

  • Sponsored research: NGM Biopharmaceuticals
  • Consulting: Bausch + Lomb, AsclepiX Therapeutics, Gyroscope, Apellis Pharmaceuticals, Genentech, Novartis, Regeneron Pharmaceuticals, and ZEISS
CME Content Review

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
  • Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
  • Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
  • Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
  • Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
  • Daniel Dasilva, Outcomes and Accreditation Coordinator of Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

RELEASE DATE: April 29, 2022

EXPIRATION DATE: April 29, 2023

PROGRAM OVERVIEW

This enduring activity targets healthcare gaps related to the early intervention of retinal vascular diseases and familiarity with new and emerging clinical trial data, impacting outcomes through assessment and synthesis of clinical trial structures, and outcomes of studied anti-VEGF agents for incorporation into treatment strategy development.

  • By addressing these gaps, you can assess whether your approach to DR, AMD, RVO, mCNV, and PCV management best applies clinical trial data to create individualized treatment regimens – or could be modified to help close these gaps.
  • Expert discussion will guide you in comparing different modalities of treatment, including efficacy, durability, and challenges related to timely treatment.
  • You will also be engaged with immersive animations in a whiteboard platform to memorably highlight key points related to clinical trials in mCNV, and PCV.
TARGET AUDIENCE

This activity is designed to meet the educational needs of clinicians in ophthalmology or retina fellowships who manage patients with Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), Retinal Vein Occlusion (RVO), Myopic Choroidal Neovascularization (mCNV), and Polypoidal Choroidal Vasculopathy (PCV).

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Utilize an understanding of the pathogenesis of DR, AMD, RVO, mCNV, and PCV to educate patients on the importance of proper eye care and early intervention in preventing progressive visual changes
  • Evaluate clinical trial data on the efficacy and safety of VEGF inhibitors in the management of DR, AMD, RVO, mCNV, and PCV
  • Incorporate clinical trial data into evidence-based treatment plans for the management of patients with DR, AMD, RVO, mCNV, and PCV
ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with diabetic retinopathy.
CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Rishi P. Singh, MD discloses the following:

  • Sponsored research: NGM Biopharmaceuticals
  • Consulting: Bausch + Lomb, AsclepiX Therapeutics, Gyroscope, Apellis Pharmaceuticals, Genentech, Novartis, Regeneron Pharmaceuticals, and ZEISS
CME Content Review

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
  • Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
  • Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
  • Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
  • Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
  • Daniel Dasilva, Outcomes and Accreditation Coordinator of Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

RELEASE DATE: April 29, 2022

EXPIRATION DATE: April 29, 2023

Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

VIEW ACTIVITY

A Virtual Reality Learning Experience: Integrating GLP-1 Receptor Agonists into T2DM Practice—Why, When, and How

Apr
29
Fri
Incorporating Clinical Trials Data into the Management of DR, AMD, RVO, mCNV, and PCV
Apr 29 2022 @ 8:00 am – Apr 29 2023 @ 9:00 am

Incorporating Clinical Trials Data into the Management of DR, AMD, RVO, mCNV, and PCV

VIEW ACTIVITY

FACULTY

Rishi P. Singh, MD
Staff Physician, Cleveland Clinic Florida
Professor of Ophthalmology
Cleveland Clinic Lerner College of Medicine
Stuart, FL

PROGRAM OVERVIEW

This enduring activity targets healthcare gaps related to the early intervention of retinal vascular diseases and familiarity with new and emerging clinical trial data, impacting outcomes through assessment and synthesis of clinical trial structures, and outcomes of studied anti-VEGF agents for incorporation into treatment strategy development.

  • By addressing these gaps, you can assess whether your approach to DR, AMD, RVO, mCNV, and PCV management best applies clinical trial data to create individualized treatment regimens – or could be modified to help close these gaps.
  • Expert discussion will guide you in comparing different modalities of treatment, including efficacy, durability, and challenges related to timely treatment.
  • You will also be engaged with immersive animations in a whiteboard platform to memorably highlight key points related to clinical trials in mCNV, and PCV.
TARGET AUDIENCE

This activity is designed to meet the educational needs of clinicians in ophthalmology or retina fellowships who manage patients with Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), Retinal Vein Occlusion (RVO), Myopic Choroidal Neovascularization (mCNV), and Polypoidal Choroidal Vasculopathy (PCV).

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Utilize an understanding of the pathogenesis of DR, AMD, RVO, mCNV, and PCV to educate patients on the importance of proper eye care and early intervention in preventing progressive visual changes
  • Evaluate clinical trial data on the efficacy and safety of VEGF inhibitors in the management of DR, AMD, RVO, mCNV, and PCV
  • Incorporate clinical trial data into evidence-based treatment plans for the management of patients with DR, AMD, RVO, mCNV, and PCV
ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with diabetic retinopathy.
CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Rishi P. Singh, MD discloses the following:

  • Sponsored research: NGM Biopharmaceuticals
  • Consulting: Bausch + Lomb, AsclepiX Therapeutics, Gyroscope, Apellis Pharmaceuticals, Genentech, Novartis, Regeneron Pharmaceuticals, and ZEISS
CME Content Review

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
  • Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
  • Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
  • Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
  • Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
  • Daniel Dasilva, Outcomes and Accreditation Coordinator of Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

RELEASE DATE: April 29, 2022

EXPIRATION DATE: April 29, 2023

PROGRAM OVERVIEW

This enduring activity targets healthcare gaps related to the early intervention of retinal vascular diseases and familiarity with new and emerging clinical trial data, impacting outcomes through assessment and synthesis of clinical trial structures, and outcomes of studied anti-VEGF agents for incorporation into treatment strategy development.

  • By addressing these gaps, you can assess whether your approach to DR, AMD, RVO, mCNV, and PCV management best applies clinical trial data to create individualized treatment regimens – or could be modified to help close these gaps.
  • Expert discussion will guide you in comparing different modalities of treatment, including efficacy, durability, and challenges related to timely treatment.
  • You will also be engaged with immersive animations in a whiteboard platform to memorably highlight key points related to clinical trials in mCNV, and PCV.
TARGET AUDIENCE

This activity is designed to meet the educational needs of clinicians in ophthalmology or retina fellowships who manage patients with Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), Retinal Vein Occlusion (RVO), Myopic Choroidal Neovascularization (mCNV), and Polypoidal Choroidal Vasculopathy (PCV).

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Utilize an understanding of the pathogenesis of DR, AMD, RVO, mCNV, and PCV to educate patients on the importance of proper eye care and early intervention in preventing progressive visual changes
  • Evaluate clinical trial data on the efficacy and safety of VEGF inhibitors in the management of DR, AMD, RVO, mCNV, and PCV
  • Incorporate clinical trial data into evidence-based treatment plans for the management of patients with DR, AMD, RVO, mCNV, and PCV
ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with diabetic retinopathy.
CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Rishi P. Singh, MD discloses the following:

  • Sponsored research: NGM Biopharmaceuticals
  • Consulting: Bausch + Lomb, AsclepiX Therapeutics, Gyroscope, Apellis Pharmaceuticals, Genentech, Novartis, Regeneron Pharmaceuticals, and ZEISS
CME Content Review

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
  • Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
  • Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
  • Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
  • Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
  • Daniel Dasilva, Outcomes and Accreditation Coordinator of Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

RELEASE DATE: April 29, 2022

EXPIRATION DATE: April 29, 2023

Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

VIEW ACTIVITY

Apr
29
Fri
Incorporating Clinical Trials Data into the Management of DR, AMD, RVO, mCNV, and PCV
Apr 29 2022 @ 8:00 am – Apr 29 2023 @ 9:00 am

Incorporating Clinical Trials Data into the Management of DR, AMD, RVO, mCNV, and PCV

VIEW ACTIVITY

FACULTY

Rishi P. Singh, MD
Staff Physician, Cleveland Clinic Florida
Professor of Ophthalmology
Cleveland Clinic Lerner College of Medicine
Stuart, FL

PROGRAM OVERVIEW

This enduring activity targets healthcare gaps related to the early intervention of retinal vascular diseases and familiarity with new and emerging clinical trial data, impacting outcomes through assessment and synthesis of clinical trial structures, and outcomes of studied anti-VEGF agents for incorporation into treatment strategy development.

  • By addressing these gaps, you can assess whether your approach to DR, AMD, RVO, mCNV, and PCV management best applies clinical trial data to create individualized treatment regimens – or could be modified to help close these gaps.
  • Expert discussion will guide you in comparing different modalities of treatment, including efficacy, durability, and challenges related to timely treatment.
  • You will also be engaged with immersive animations in a whiteboard platform to memorably highlight key points related to clinical trials in mCNV, and PCV.
TARGET AUDIENCE

This activity is designed to meet the educational needs of clinicians in ophthalmology or retina fellowships who manage patients with Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), Retinal Vein Occlusion (RVO), Myopic Choroidal Neovascularization (mCNV), and Polypoidal Choroidal Vasculopathy (PCV).

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Utilize an understanding of the pathogenesis of DR, AMD, RVO, mCNV, and PCV to educate patients on the importance of proper eye care and early intervention in preventing progressive visual changes
  • Evaluate clinical trial data on the efficacy and safety of VEGF inhibitors in the management of DR, AMD, RVO, mCNV, and PCV
  • Incorporate clinical trial data into evidence-based treatment plans for the management of patients with DR, AMD, RVO, mCNV, and PCV
ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with diabetic retinopathy.
CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Rishi P. Singh, MD discloses the following:

  • Sponsored research: NGM Biopharmaceuticals
  • Consulting: Bausch + Lomb, AsclepiX Therapeutics, Gyroscope, Apellis Pharmaceuticals, Genentech, Novartis, Regeneron Pharmaceuticals, and ZEISS
CME Content Review

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
  • Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
  • Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
  • Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
  • Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
  • Daniel Dasilva, Outcomes and Accreditation Coordinator of Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

RELEASE DATE: April 29, 2022

EXPIRATION DATE: April 29, 2023

PROGRAM OVERVIEW

This enduring activity targets healthcare gaps related to the early intervention of retinal vascular diseases and familiarity with new and emerging clinical trial data, impacting outcomes through assessment and synthesis of clinical trial structures, and outcomes of studied anti-VEGF agents for incorporation into treatment strategy development.

  • By addressing these gaps, you can assess whether your approach to DR, AMD, RVO, mCNV, and PCV management best applies clinical trial data to create individualized treatment regimens – or could be modified to help close these gaps.
  • Expert discussion will guide you in comparing different modalities of treatment, including efficacy, durability, and challenges related to timely treatment.
  • You will also be engaged with immersive animations in a whiteboard platform to memorably highlight key points related to clinical trials in mCNV, and PCV.
TARGET AUDIENCE

This activity is designed to meet the educational needs of clinicians in ophthalmology or retina fellowships who manage patients with Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), Retinal Vein Occlusion (RVO), Myopic Choroidal Neovascularization (mCNV), and Polypoidal Choroidal Vasculopathy (PCV).

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Utilize an understanding of the pathogenesis of DR, AMD, RVO, mCNV, and PCV to educate patients on the importance of proper eye care and early intervention in preventing progressive visual changes
  • Evaluate clinical trial data on the efficacy and safety of VEGF inhibitors in the management of DR, AMD, RVO, mCNV, and PCV
  • Incorporate clinical trial data into evidence-based treatment plans for the management of patients with DR, AMD, RVO, mCNV, and PCV
ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with diabetic retinopathy.
CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Rishi P. Singh, MD discloses the following:

  • Sponsored research: NGM Biopharmaceuticals
  • Consulting: Bausch + Lomb, AsclepiX Therapeutics, Gyroscope, Apellis Pharmaceuticals, Genentech, Novartis, Regeneron Pharmaceuticals, and ZEISS
CME Content Review

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
  • Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
  • Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
  • Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
  • Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
  • Daniel Dasilva, Outcomes and Accreditation Coordinator of Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

RELEASE DATE: April 29, 2022

EXPIRATION DATE: April 29, 2023

Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

VIEW ACTIVITY

Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.